Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged BioSpaceAfter devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving.Read full story pharminent May 13, 2026 (Last updated: May 13, 2026) BioSpace After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Assertio accepts new buyout bid; AI biotech Isomorphic banks $2BNext: FDA’s leadership void leaves biotech with renewed ‘uncertainty’ Related Stories Policy / Pricing US launches probe of German ‘underpayment’ for medicines pharminent June 19, 2026 Policy / Pricing FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ pharminent June 19, 2026 Policy / Pricing German said to be backtracking on pharma rebate changes pharminent June 16, 2026
